Articles

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy

Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme enzyme that catalyzes the oxidation of L-tryptophan. Functionally, IDO1 has played a pivotal role in cancer immune escape via catalyzing the initial step of the kynu...

Authors: Kai Tang, Ya-Hong Wu, Yihui Song and Bin Yu

Targeting MCL-1 in cancer: current status and perspectives

Myeloid leukemia 1 (MCL-1) is an antiapoptotic protein of the BCL-2 family that prevents apoptosis by binding to the pro-apoptotic BCL-2 proteins. Overexpression of MCL-1 is frequently observed in many tumor t...

Authors: Haolan Wang, Ming Guo, Hudie Wei and Yongheng Chen

Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Antibodies and chimeric antigen receptor-engineered T cells (CAR-T) are increasingly used for cancer immunotherapy. Small molecule inhibitors targeting cellular oncoproteins and enzymes such as BCR-ABL, JAK2, ...

Authors: Jing-Zhou Hou, Jing Christine Ye, Jeffrey J. Pu, Hongtao Liu, Wei Ding, Hong Zheng and Delong Liu

CAR-T cells and BiTEs in solid tumors: challenges and perspectives

Chimeric antigen receptor (CAR)-modified T cells and BiTEs are both immunotherapies which redirect T cell specificity against a tumor-specific antigen through the use of antibody fragments. They demonstrated r...

Authors: Julien Edeline, Roch Houot, Aurélien Marabelle and Marion Alcantara

Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study

The onset of the COVID-19 pandemic forced the Dutch national screening program to a halt and increased the burden on health care services, necessitating the introduction of specific breast cancer treatment rec...

Authors: Anouk H. Eijkelboom, Linda de Munck, Marie-Jeanne T. F. D. Vrancken Peeters, Mireille J. M. Broeders, Luc J. A. Strobbe, Monique E. M. M. Bos, Marjanka K. Schmidt, Cristina Guerrero Paez, Marjolein L. Smidt, Maud Bessems, Janneke Verloop, Sabine Linn, Marc B. I. Lobbes, Aafke H. Honkoop, Desirée H. J. G. van den Bongard, Pieter J. Westenend…

Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies

Bispecific T cell engagers (BiTEs) are an innovative class of immunotherapeutics that redirect T cells to tumor surface antigens. While efficacious against certain hematological malignancies, limited bioavaila...

Authors: Johannes P. W. Heidbuechel and Christine E. Engeland

Stop hate crimes and racism

Authors:

Correction to: Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells

An amendment to this paper has been published and can be accessed via the original article.

Authors: Yahui Ding, Huier Gao, Yu Zhang, Ye Li, Neil Vasdev, Yingdai Gao, Yue Chen and Quan Zhang

CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer

Both aberrant alternative splicing and m6A methylation play complicated roles in the development of pancreatic cancer (PC), while the relationship between these two RNA modifications remains unclear.

Authors: Shi Chen, Can Yang, Zu-Wei Wang, Jian-Fei Hu, Jing-Jing Pan, Cheng-Yu Liao, Jia-Qiang Zhang, Jiang-Zhi Chen, Yi Huang, Long Huang, Qian Zhan, Yi-Feng Tian, Bai-Yong Shen and Yao-Dong Wang

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients...

Authors: Maria V. Mateos, Maria Gavriatopoulou, Thierry Facon, Holger W. Auner, Xavier Leleu, Roman Hájek, Meletios A. Dimopoulos, Sosana Delimpasi, Maryana Simonova, Ivan Špička, Ludĕk Pour, Iryna Kriachok, Halyna Pylypenko, Vadim Doronin, Ganna Usenko, Reuben Benjamin…

Lactoferrin is required for early B cell development in C57BL/6 mice

Lactoferrin (Lf) is widely distributed in mammalian milk, various tissues, and their exocrine fluids and has many physiological functions, such as bacteriostasis, antivirus, and immunoregulation. Here, we prov...

Authors: Lingyu Wei, Can Liu, Jia Wang, Xiang Zheng, Qiu Peng, Qiurong Ye, Zailong Qin, Zhengshuo Li, Xiaoyue Zhang, Yangge Wu, Yuqing Wen, Xuemei Zhang, Qun Yan and Jian Ma

Targeting neddylation E2s: a novel therapeutic strategy in cancer

Ubiquitin-conjugating enzyme E2 M (UBE2M) and ubiquitin-conjugating enzyme E2 F (UBE2F) are the two NEDD8-conjugating enzymes of the neddylation pathway that take part in posttranslational modification and cha...

Authors: Yi-Chao Zheng, Yan-Jia Guo, Bo Wang, Chong Wang, M. A. A. Mamun, Ya Gao and Hong-Min Liu

Structure, function and inhibition of critical protein–protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins

Mixed lineage leukemia 1 (MLL1, also known as MLL or KMT2A) is an important transcription factor and histone-H3 lysine-4 (H3K4) methyltransferase. It is a master regulator for transcription of important genes ...

Authors: Xin Li and Yongcheng Song

Novel therapies emerging in oncology to target the TGF-β pathway

The TGF-β signaling pathway governs key cellular processes under physiologic conditions and is deregulated in many pathologies, including cancer. TGF-β is a multifunctional cytokine that acts in a cell- and co...

Authors: Byung-Gyu Kim, Ehsan Malek, Sung Hee Choi, James J. Ignatz-Hoover and James J. Driscoll

HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA

N6-methyladenosine (m6A) modification is the most prevalent modification in eukaryotic RNAs while accumulating studies suggest that m6A aberrant expression plays an important role in cancer. HNRNPA2B1 is a m6A...

Authors: Fengjie Jiang, Xiaozhu Tang, Chao Tang, Zhen Hua, Mengying Ke, Chen Wang, Jiamin Zhao, Shengyao Gao, Artur Jurczyszyn, Siegfried Janz, Meral Beksac, Fenghuang Zhan, Chunyan Gu and Ye Yang

Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Non-T-cell depleted haploidentical hematopoietic stem cell transplantation (HaploSCT) is being increasingly used in acute lymphoblastic leukemia (ALL) with improving patient outcomes. We have recently reported...

Authors: Arnon Nagler, Myriam Labopin, Mohamed Houhou, Mahmoud Aljurf, Ashrafsadat Mousavi, Rose-Marie Hamladji, Mohsen Al Zahrani, Sergey Bondarenko, Mutlu Arat, Emanuele Angelucci, Yener Koc, Zafer Gülbas, Simona Sica, Jean Henri Bourhis, Jonathan Canaani, Eolia Brissot…

Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice

Frameshifts in the Calreticulin (CALR) exon 9 provide a recurrent driver mutation of essential thrombocythemia (ET) and primary myelofibrosis among myeloproliferative neoplasms (MPNs). Here, we generated knock-in...

Authors: Keiji Minakawa, Tetsuro Yokokawa, Koki Ueda, Osamu Nakajima, Tomofumi Misaka, Yusuke Kimishima, Kento Wada, Yusuke Tomita, Saori Miura, Yuka Sato, Kosaku Mimura, Koichi Sugimoto, Kazuhiko Nakazato, Kenneth E. Nollet, Kazuei Ogawa, Takayuki Ikezoe…

Prostate cancer and PARP inhibitors: progress and challenges

Despite survival improvements achieved over the last two decades, prostate cancer remains lethal at the metastatic castration-resistant stage (mCRPC) and new therapeutic approaches are needed. Germinal and/or ...

Authors: Diego Teyssonneau, Henri Margot, Mathilde Cabart, Mylène Anonnay, Paul Sargos, Nam-Son Vuong, Isabelle Soubeyran, Nicolas Sevenet and Guilhem Roubaud

Therapeutic strategies in RET gene rearranged non-small cell lung cancer

The recent approvals by the Food and Drug Administration several tumor-agnostic drugs have resulted in a paradigm shift in cancer treatment from an organ/histology-specific strategy to biomarker-guided approac...

Authors: Leylah M. Drusbosky, Estelamari Rodriguez, Richa Dawar and Chukwuemeka V. Ikpeazu

Emerging agents and regimens for AML

Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options, depending solely on cytarabine + anthracycline (7 + 3) intensive chemotherapy and hypomethylating agents. Allogenei...

Authors: Hongtao Liu

Targeting chemokines for acute lymphoblastic leukemia therapy

Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by the malignant clonal expansion of lymphoid hematopoietic precursors. It is regulated by various signaling molecules such as cyt...

Authors: Zixi Hong, Zimeng Wei, Tian Xie, Lin Fu, Jiaxing Sun, Fuling Zhou, Muhammad Jamal, Qiuping Zhang and Liang Shao

Reduction of RUNX1 transcription factor activity by a CBFA2T3-mimicking peptide: application to B cell precursor acute lymphoblastic leukemia

B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is the most common pediatric cancer. Identifying key players involved in proliferation of BCP-ALL cells is crucial to propose new therapeutic targets. Ru...

Authors: Hélène Jakobczyk, Lydie Debaize, Benoit Soubise, Stéphane Avner, Jérémie Rouger-Gaudichon, Séverine Commet, Yan Jiang, Aurélien A. Sérandour, Anne-Gaëlle Rio, Jason S. Carroll, Christian Wichmann, Michael Lie-a-Ling, Georges Lacaud, Laurent Corcos, Gilles Salbert, Marie-Dominique Galibert…

Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N⁶-methyladenosine of PARP1 mRNA and downregulating PTEN

NONO-TFE3 translocation renal cell carcinoma (NONO-TFE3 tRCC) is one subtype of RCCs associated with Xp11.2 translocation/TFE3 gene fusions RCC (Xp11.2 tRCCs). Long non-coding RNA (lncRNA) has attracted great att...

Authors: Lei Yang, Yi Chen, Ning Liu, QianCheng Shi, Xiaodong Han, Weidong Gan and Dongmei Li

Next generation of immune checkpoint inhibitors and beyond

The immune system is the core defense against cancer development and progression. Failure of the immune system to recognize and eliminate malignant cells plays an important role in the pathogenesis of cancer. ...

Authors: Julian A. Marin-Acevedo, ErinMarie O. Kimbrough and Yanyan Lou

Third-line therapy for chronic myeloid leukemia: current status and future directions

Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome. The BCR-ABL1 fusion protein is an optim...

Authors: Jorge Cortes and Fabian Lang

Cell-permeable transgelin-2 as a potent therapeutic for dendritic cell-based cancer immunotherapy

Transgelin-2 is a 22 kDa actin-binding protein that has been proposed to act as an oncogenic factor, capable of contributing to tumorigenesis in a wide range of human malignancies. However, little is known whe...

Authors: Hye-Ran Kim, Jeong-Su Park, Jin-Hwa Park, Fatima Yasmin, Chang-Hyun Kim, Se Kyu Oh, Ik-Joo Chung and Chang-Duk Jun

Correction to: The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia

The original article [1] contains an error in Fig. 6b for the image of western blot panels.

Authors: Wen-Tao Wang, Tian-Qi Chen, Zhan-Cheng Zeng, Qi Pan, Wei Huang, Cai Han, Ke Fang, Lin-Yu Sun, Qian-Qian Yang, Dan Wang, Xue-Qun Luo, Yu-Meng Sun and Yue-Qin Chen

Regulatory mechanisms, functions, and clinical significance of CircRNAs in triple-negative breast cancer

Circular RNAs (circRNAs) are a new class of endogenous regulatory RNAs characterized by covalently closed cyclic structure lacking poly-adenylated tails, and are capable of regulating gene expression at transc...

Authors: Lijuan Lyu, Shizhen Zhang, Yujiao Deng, Meng Wang, Xinyue Deng, Si Yang, Ying Wu and Zhijun Dai

Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies

B cell receptor (BCR) signaling is involved in the pathogenesis of B cell malignancies. Activation of BCR signaling promotes the survival and proliferation of malignant B cells. Bruton tyrosine kinase (BTK) is...

Authors: Danling Gu, Hanning Tang, Jiazhu Wu, Jianyong Li and Yi Miao

Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancers

Immune checkpoint therapy (ICT) can produce durable antitumor responses in various cancer types; however, the responses are not universal, and the predictive biomarkers are urgently needed. Growing evidence po...

Authors: Peng Zhang and Yixuan Huang

COVID-19 vaccines for patients with cancer: benefits likely outweigh risks

Less than a year since the start of the COVID-19 pandemic, ten vaccines against SARS-CoV-2 have been approved for at least limited use, with over sixty others in clinical trials. This swift achievement has gen...

Authors: Joyce K. Hwang, Tian Zhang, Andrew Z. Wang and Zihai Li

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia

Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks in adults with immune thrombocytopenia (ITP). This phase III study ...

Authors: Heng Mei, Xiaofan Liu, Yan Li, Hu Zhou, Ying Feng, Guangxun Gao, Peng Cheng, Ruibin Huang, Linhua Yang, Jianda Hu, Ming Hou, Yazhou Yao, Li Liu, Yi Wang, Depei Wu, Liansheng Zhang…

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

B-cell receptor (BCR) antagonists such as the BTK inhibitor ibrutinib have proven to effectively target chronic lymphocytic leukemia (CLL) tumor cells, leading to impressive response rates in these patients. H...

Authors: Timothy L. Chen, Bonnie Harrington, Jean Truxall, Ronni Wasmuth, Alexander Prouty, Shelby Sloan, Amy M. Lehman, Deepa Sampath, Eric Orlemans, Robert A. Baiocchi, Lapo Alinari, John C. Byrd, Jennifer A. Woyach and Erin Hertlein

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

Moxetumomab pasudotox is a recombinant CD22-targeting immunotoxin. Here, we present the long-term follow-up analysis of the pivotal, multicenter, open-label trial (NCT01829711) of moxetumomab pasudotox in pati...

Authors: Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Tadeusz Robak, Philipp D. le Coutre, Bjørn T. Gjertsen, Xavier Troussard, Gail J. Roboz, Lionel Karlin, Douglas E. Gladstone, Nataliya Kuptsova-Clarkson, Shiyao Liu, Priti Patel, Federico Rotolo, Emmanuel Mitry…

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

An amendment to this paper has been published and can be accessed via the original article.

Authors: Musa Yilmaz, Mansour Alfayez, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Marina Y. Konopleva, Sanam Loghavi, Rashmi Kanagal-Shamanna, Keyur P. Patel, Elias J. Jabbour, Guillermo Garcia‑Manero, Naveen Pemmaraju, Sherry A. Pierce, Issa Ghayas, Nicholas J. Short, Guillermo Montalban-Bravo…

Correction to: Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer

An amendment to this paper has been published and can be accessed via the original article.

Authors: Senlin Zhao, Yushuai Mi, Bingjie Guan, Binbin Zheng, Ping Wei, Yanzi Gu, Zhengxiang Zhang, Sanjun Cai, Ye Xu, Xinxiang Li, Xuefeng He, Xinyang Zhong, Guichao Li, Zhiyu Chen and Dawei Li

m⁶A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis

Authors: Dan Jin, Jiwei Guo, Yan Wu, Jing Du, Lijuan Yang, Xiaohong Wang, Weihua Di, Baoguang Hu, Jiajia An, Lingqun Kong, Lei Pan and Guoming Su

Correction to: MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents

An amendment to this paper has been published and can be accessed via the original article.

Authors: Arnold Bolomsky, Meike Vogler, Murat Cem Köse, Caroline A. Heckman, Grégory Ehx, Heinz Ludwig and Jo Caers

The emerging role of KDM5A in human cancer

Histone methylation is a key posttranslational modification of chromatin, and its dysregulation affects a wide array of nuclear activities including the maintenance of genome integrity, transcriptional regulat...

Authors: Guan-Jun Yang, Ming-Hui Zhu, Xin-Jiang Lu, Yan-Jun Liu, Jian-Fei Lu, Chung-Hang Leung, Dik-Lung Ma and Jiong Chen

Correction to: The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma

An amendment to this paper has been published and can be accessed via the original article.

Authors: Zemin Ren, Hildo Lantermans, Annemieke Kuil, Willem Kraan, Fernando Arenzana-Seisdedos, Marie José Kersten, Marcel Spaargaren and Steven T. Pals

Correction to: Novel and emerging therapies for B cell lymphoma

An amendment to this paper has been published and can be accessed via the original article.

Authors: Sabarish Ayyappan and Kimi Maddocks

The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

Therapeutic antibodies targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis induce potent and durable anti-tumor responses in multiple types of cancers. However, only a subse...

Authors: Ming Yi, Jing Zhang, Anping Li, Mengke Niu, Yongxiang Yan, Ying Jiao, Suxia Luo, Pengfei Zhou and Kongming Wu

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies

CD19-targeted chimeric antigen receptor T (CAR T) cell therapy is a promising option to treat relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). However, the majority of CAR T-treated patients will...

Authors: Yun Liang, Hui Liu, Zheming Lu, Wen Lei, Chaoting Zhang, Ping Li, Aibin Liang, Ken H. Young and Wenbin Qian

Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Natural killer/T-cell lymphoma (NKTCL) is a disease with limited treatment options and poor outcomes. Daratumumab monotherapy demonstrated clinical activity in a single-patient case report. We present data fro...

Authors: Huiqiang Huang, Jun Zhu, Ming Yao, Tae Min Kim, Dok Hyun Yoon, Seok-Goo Cho, Hyeon Seok Eom, Soon Thye Lim, Su-peng Yeh, Yuqin Song, Yok Lam Kwong, Jin Seok Kim, Jie Jin, Yuankai Shi, HyeJin Kim, Min Qing…

Challenges and advances in clinical applications of mesenchymal stromal cells

Mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, have been intensely investigated for clinical applications within the last decades. However, the majority of registered clinical trials a...

Authors: Tian Zhou, Zenan Yuan, Jianyu Weng, Duanqing Pei, Xin Du, Chang He and Peilong Lai

FGFR-TKI resistance in cancer: current status and perspectives

Fibroblast growth factor receptors (FGFRs) play key roles in promoting the proliferation, differentiation, and migration of cancer cell. Inactivation of FGFRs by tyrosine kinase inhibitors (TKI) has achieved g...

Authors: Sitong Yue, Yukun Li, Xiaojuan Chen, Juan Wang, Meixiang Li, Yongheng Chen and Daichao Wu

Clonal evolution in liver cancer at single-cell and single-variant resolution

Genetic heterogeneity of tumor is closely related to its clonal evolution, phenotypic diversity and treatment resistance, and such heterogeneity has only been characterized at single-cell sub-chromosomal scale...

Authors: Xianbin Su, Linan Zhao, Yi Shi, Rui Zhang, Qi Long, Shihao Bai, Qing Luo, Yingxin Lin, Xin Zou, Shila Ghazanfar, Kun Tao, Guoliang Yang, Lan Wang, Kun-Yan He, Xiaofang Cui, Jian He…

Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes

B7-H3, an immune-checkpoint molecule and a transmembrane protein, is overexpressed in non-small cell lung cancer (NSCLC), making it an attractive therapeutic target. Here, we aimed to systematically evaluate t...

Authors: Jie Liu, Shuo Yang, Bihui Cao, Guangyu Zhou, Fengjuan Zhang, Yuan Wang, Rixin Wang, Lipeng Zhu, Ya Meng, Cong Hu, Hui Liang, Xu Lin, Kangshun Zhu, Guokai Chen, Kathy Qian Luo, Lijun Di…

Antibody–drug conjugates in solid tumors: a look into novel targets

Antibody–drug conjugates (ADCs) are a relatively new class of anticancer agents designed to merge the selectivity of monoclonal antibodies with cell killing properties of chemotherapy. They are commonly descri...

Authors: Carmen Criscitiello, Stefania Morganti and Giuseppe Curigliano

Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells

TNBC is the most aggressive breast cancer with higher recurrence and mortality rate than other types of breast cancer. There is an urgent need for identification of therapeutic agents with unique mode of actio...

Authors: Yahui Ding, Xiaoping Chen, Can Liu, Weizhi Ge, Qin Wang, Xin Hao, Mengmeng Wang, Yue Chen and Quan Zhang